Crefmirlimab
Based on 1 Customer Validation
Crefmirlimab (IAB22M2C; ImaginAb) is a humanized CD8-specific single-domain antibody. Conjugation of Crefmirlimab with radioisotopes (e.g., 89Zr) enables tumor immune infiltration assessment, autoimmune disease detection, and immunotherapy response monitoring. Crefmirlimab is applicable for cancer research.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 97.616%
- CAS No.: 2611099-93-3
- Masse moléculaire:79.946 kDa
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Description
Isotype
(scFv-kappa-heavy)-h-CH3
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
CD8A
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:NOD-SCID IL-2Rγ null (NSG) (female)[1]
-
Dosage:48-81 μCi (delivering ~50 μg)
-
Administration:i.v.
-
Result:Showed substantial uptake in CD8+ T cell-rich tissues (spleen and tumors) with minimal accumulation in background tissues (muscle, whole blood).
Detected dose-dependent increases in tumor uptake on day 9 post-bispecific antibody treatment, with a mean SUV of up to 1.54 (SEM) in the highest-dose bispecific antibody group.
Confirmed dose- and time-dependent tumor uptake via ex vivo gamma counting, with a mean tumor uptake of 13.0%ID/g (SEM) in the highest-dose bispecific antibody group on day 9.
Showed moderate correlation between tumor radiotracer uptake (SUV or %ID/g) and CD8+ T cell density via immunohistochemistry (R2 = 0.46 and R2 = 0.45, respectively) on day 9.
Achieved tumor-to-blood ratios >8 and tumor-to-muscle ratios >27 for the highest bispecific antibody dose on day 9.
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
(scFv-kappa-heavy)-h-CH3
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized CD8 alpha Protein, Human (HEK293, His, HY-P71662) can bind Crefmirlimab. The EC50 for this effect is 532.3 ng/mL.
Chemical Information
-
CAS No. 2611099-93-3
-
Appearance Liquid
-
Masse moléculaire 79.946 kDa
-
Color Colorless to light yellow
-
SMILES
[Crefmirlimab]
-
Synonyms
IAB22M2C; ImaginAb
-
Livraison
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
-
Fiche technique (261 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Crefmirlimab Related Classifications
HY-P99834 Related Classifications
Powered by Bioz